Copyright
©The Author(s) 2025.
World J Gastroenterol. Mar 7, 2025; 31(9): 100271
Published online Mar 7, 2025. doi: 10.3748/wjg.v31.i9.100271
Published online Mar 7, 2025. doi: 10.3748/wjg.v31.i9.100271
Table 1 Scoring criteria for inflammation-associated histological changes
| Score | Inflammation | Crypt damage | Ulceration | Edema |
| 0 | No infiltrate | None | None | Absent |
| 1 | Occasional cells limited to submucosa | Some crypt damage, spaces between crypts | Small, focal ulcers | Present |
| 2 | Significant presence of inflammatory cells in submucosa limited to focal areas | Larger spaces between crypts, loss of goblet cells, some shortening of crypts | Frequent small ulcers | - |
| 3 | Infiltrate is present in both submucosa and lamina propria, limited to focal areas | Large areas without crypts, surrounded by normal crypts | Large areas lacking surface epithelium | - |
| 4 | A large amount of infiltrate in the submucosa, lamina propria, and surrounding blood vessels, covering large areas of mucosa | No crypts | - | - |
| 5 | Transmural inflammation (mucosa to muscularis) | - | - | - |
Table 2 Primers for real time-quantitative PCR
| Gene | Forward | Reverse |
| TNF-α | 5′-CCCCAAAGGGATGAGAAGTTC-3′ | 5′-CCTCCACTTGGTGGTTTGCT-3′ |
| IL-1β | 5′-GTTCCCATTAGACAACTGCACTACAG-3′ | 5′-GTCGTTGCTTGGTTCTCCTTGTA-3′ |
| IL-6 | 5′-CCAGAAACCGCTATGAAGTTCC-3′ | 5′-GTTGGGAGTGGTATCCTCTGTGA-3′ |
| COX2 | 5′-CAGTTTATGTTGTCTGTCCAGAGTTTC-3′ | 5′-CCAGCACTTCACCCATCAGTT-3 |
| iNOS | 5′-GAACTGTAGCACAGCACAGGAAAT-3′ | 5′-CGTACCGGATGAGCTGTGAAT-3′ |
| β-Actin | 5′-GTCAGGTCATCACTATCGGCAAT-3′ | 5′-AGAGGTCTTTACGGATGTCAACGT-3′ |
Table 3 Parameters of active ingredients of Panax ginseng
| Active ingredient | Degree | Betweenness | Closeness |
| Gomisin B | 35.0 | 1180.6964 | 0.46575344 |
| Ginsenoside-Rh4_qt | 32.0 | 1050.481 | 0.4573991 |
| Deoxyharringtonine | 31.0 | 1032.064 | 0.45333335 |
| Ginsenoside Rg5_qt | 30.0 | 872.32416 | 0.4493392 |
| Panaxadiol | 29.0 | 995.441 | 0.44541484 |
| Girinimbin | 28.0 | 1012.3926 | 0.44155845 |
| Celabenzine | 26.0 | 677.8078 | 0.43404254 |
| Alexandrin_qt | 25.0 | 728.7032 | 0.43037975 |
| Aposiopolamine | 24.0 | 684.26025 | 0.42677826 |
| Suchilactone | 24.0 | 540.3291 | 0.42323652 |
| Arachidonate | 23.0 | 651.64233 | 0.42323652 |
| Kaempferol | 19.0 | 426.3942 | 0.40963855 |
| Beta-sitosterol | 18.0 | 342.33905 | 0.4063745 |
| Stigmasterol | 18.0 | 352.47723 | 0.4063745 |
| Inermin | 17.0 | 323.1763 | 0.40316206 |
| Fumarine | 15.0 | 223.88904 | 0.39688715 |
| Frutinone A | 11.0 | 144.62103 | 0.38490567 |
| Ginsenoside rh2 | 6.0 | 32.973564 | 0.3709091 |
| Dianthramine | 4.0 | 21.07494 | 0.3655914 |
| Diop | 2.0 | 2.9129128 | 0.36042404 |
- Citation: Qin Y, Zhang RY, Zhang Y, Zhao YQ, Hao HF, Wang JP. Network pharmacology and in vivo study: Unraveling the therapeutic mechanisms of Panax ginseng in potentially treating ulcerative colitis. World J Gastroenterol 2025; 31(9): 100271
- URL: https://www.wjgnet.com/1007-9327/full/v31/i9/100271.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i9.100271
